The emerging pipeline for Peripheral Arterial Disease majorly comprises cell therapies. Ixaka’s REX-001, Hemostemix’s ACP-01, Humacyte’s Human Acellular Vessel (HAV), and Caladrius Bioscience’s Honedra are the most highlighted emerging therapies. The emerging therapies are in the late, middle, and early stages of development. Some of these emerging therapies are expected to enter the market in the near future.
DelveInsight’s “Peripheral Arterial Disease (PAD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Peripheral Arterial Disease Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Peripheral Arterial Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Peripheral Arterial Disease: An Overview
Peripheral Artery Disease (also called Peripheral Arterial Disease/PAD) is a common circulatory problem in which narrowed arteries reduce blood flow to limbs. In peripheral artery disease (PAD), legs or arms—usually legs—do not receive enough blood flow to keep up with demand. This may cause symptoms, such as leg pain when walking (claudication). Severe PAD can further develop into critical limb ischemia, stroke, or heart attack.
Although PAD has long been underappreciated compared with coronary artery disease (CAD) and cerebrovascular disease, it is increasingly recognized as an important cause of cardiovascular morbidity and mortality. Other health conditions and disorders of arteries can mimic Peripheral Arterial Disease symptoms, and not all PAD is due to atherosclerosis.
Peripheral Arterial Disease Market Key Facts
As per DelveInsight, in 2021, there were 36,661,865 cases of Peripheral Arterial Disease in the 7MM. Approximately 55% of cases were reported in the US, compared to about 39% cases in EU-5; Germany accounted for the highest number of cases among EU-5 countries.
According to Alzamora et al. (2016), the occurrence of Peripheral Arterial Disease is higher in men, especially .
As per DelveInsight’s estimates, Japan accounted for the lowest number of Peripheral Arterial Disease cases among the 7MM.
DelveInsight estimates that in 2021, there were 15,671,031 diagnosed prevalent PAD cases in 7MM. The highest number of cases (approximately 61%) were diagnosed in the US, followed by EU-5 and Japan.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Peripheral Arterial Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Peripheral Arterial Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Peripheral Arterial Disease (PAD) Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Peripheral Arterial Disease (PAD) Epidemiology Segmentation
Total Diagnosed Prevalent Cases of Peripheral Arterial Disease
Severity-specific Prevalent Cases of Peripheral Arterial Disease
Age-specific Prevalent Cases of Peripheral Arterial Disease
Gender-specific Cases of Peripheral Arterial Disease
Treatable Cases of Peripheral Arterial Disease
Total Prevalent Cases of Peripheral Arterial Disease
Peripheral Arterial Disease (PAD) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Peripheral Arterial Disease market or expected to get launched during the study period. The analysis covers Peripheral Arterial Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Peripheral Arterial Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Peripheral Arterial Disease Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-market
Peripheral Arterial Disease Therapeutics Analysis
With the increasing prevalent cases of peripheral artery disease and the expected launch of upcoming therapies, the Peripheral Arterial Disease market is expected to grow in the coming years.
Peripheral Arterial Disease (PAD) Therapies covered in the report include
Human Acellular Vessel (HAV)
SAKIGAKE designated Honedra (formerly known as CLBS12)
Temsirolimus adventitial delivery
And many more
Some of the key companies in the Peripheral Arterial Disease (PAD) Therapeutics Market include:
Ixaka Ltd (formerly known as Rexgenero)
New Beta Innovation Limited
And many others
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Peripheral Arterial Disease Competitive Intelligence Analysis
4. Peripheral Arterial Disease Market Overview at a Glance
5. Peripheral Arterial Disease Disease Background and Overview
6. Peripheral Arterial Disease Patient Journey
7. Peripheral Arterial Disease Epidemiology and Patient Population (In US, EU5, and Japan)
8. Peripheral Arterial Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Peripheral Arterial Disease Unmet Needs
10. Key Endpoints of Peripheral Arterial Disease Treatment
11. Peripheral Arterial Disease Marketed Products
12. Peripheral Arterial Disease Emerging Drugs and Latest Therapeutic Advances
13. Peripheral Arterial Disease Seven Major Market Analysis
14. Attribute Analysis
15. Peripheral Arterial Disease Market Outlook (In US, EU5, and Japan)
16. Peripheral Arterial Disease Access and Reimbursement Overview
17. KOL Views on the Peripheral Arterial Disease Market
18. Peripheral Arterial Disease Market Drivers
19. Peripheral Arterial Disease Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Alpha-1 Antitrypsin Deficiency (A1ATD) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Alpha-1 Antitrypsin Deficiency Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States